600566.SH
Hubei Jumpcan Pharmaceutical Co., Ltd.
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 26.71
+1.33%Oct 29, 2026, 08:42 UTC
Jichuan Pharmaceutical reported 2026 first-nine-month revenue of CNY 3.637 billion, down 7.50% year over year, and net profit attributable to shareholders of CNY 1.061 billion, up 3.77%.
Source:Oct 14, 2026, 10:38 UTC
Jichuan Pharmaceutical said deputy general manager and finance director Yan Hongquan completed a planned sale of 85,000 company shares through centralized bidding for a total of RMB 2.3171 million at RMB 27.26 per share.
Source:Oct 14, 2026, 10:38 UTC
Jichuan Pharmaceutical said employee representative director Huang Qurong and deputy general manager and finance director Yan Hongquan completed planned sales of 96,000 and 85,000 company shares, respectively, through centralized bidding.
Source:Oct 8, 2026, 10:16 UTC
Jichuan Pharmaceutical said it had repurchased 934,700 shares, or 0.10% of its total share capital, for a cumulative RMB 25.001 million at prices of RMB 25.94–27.49 per share.
Source:Sep 1, 2026, 09:43 UTC
Jichuan Pharmaceutical's employee representative director Huang Qurong reduced his shareholding by 96,000 shares on August 31, 2026, completing his reduction plan.
Source: